General Information of Drug Transporter (DT)
DT ID	DTD0008 Transporter Info
Gene Name	SLCO1B1
Protein Name	Organic anion transporting polypeptide 1B1
Gene ID	10599
UniProt ID	Q9Y6L6
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs11045819
Site of GPD	chr12:21176879 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>T
Minor Allele Frequency	A=0.0649/325 (Global)
Genotype AC	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Rifampicin	Drug Info	Healthy Individuals	Correlated with the increased drug clearance in healthy individuals (compare with genotype CC)		[ 1]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Fluvastatin	Drug Info	Hypercholesterolemia	Correlated with the decreased LDL-C reduction in patients (compare with genotypes AA + AC)		[ 2]
Genetic Polymorphism	rs11045821
Site of GPD	chr12:21179489 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	A=0.0527/264 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the decreased drug clearance in patients (compare with allele G)		[ 3]
Genetic Polymorphism	rs11045879
Site of GPD	chr12:21229685 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	C=0.2192/1098 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the decreased drug clearance in patients (compare with Allele T)		[ 3]
Allele T	Click to Show/Hide the Full List of Affected Drugs:            2 Drugs in Total
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased drug clearance in patients (compare with allele C); Correlated with the increased gastrointestinal toxicity in patients (compare with allele C)		[ 4], [ 5]
Mercaptopurine	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased gastrointestinal toxicity in patients (compare with allele C)		[ 4]
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:            2 Drugs in Total
Methotrexate	Drug Info	Osteosarcoma	Correlated with the increased drug concentrations in patients (compare with Genotype TT)		[ 6]
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Irrelevant to the drug concentrations in patients (compare with Genotype TT)		[ 7]
Genetic Polymorphism	rs113681054
Site of GPD	chr12:21250045 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	C=0.2188/1096 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Ticagrelor	N.A.	Acute Coronary Syndrome	Correlated with the increased drug concentrations in patients (compare with Allele T)		[ 8]
Genetic Polymorphism	rs2306283
Site of GPD	chr12:21176804 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G / A>T
Minor Allele Frequency	A=0.3776/1891 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the decreased drug clearance in patients (compare with allele G)		[ 3]
Allele G	Click to Show/Hide the Full List of Affected Drugs:            4 Drugs in Total
Atorvastatin	Drug Info	Coronary Artery Disease	Irrelevant to the likelihood of statin-related myopathy in patients (compare with allele A)		[ 9]
Rosuvastatin	Drug Info	Coronary Artery Disease	Irrelevant to the likelihood of statin-related myopathy in patients (compare with allele A)		[ 9]
Simvastatin	Drug Info	Coronary Artery Disease	Irrelevant to the likelihood of statin-related myopathy in patients (compare with allele A)		[ 9]
Hmg coa reductase inhibitors	N.A.	Diabetes Mellitus	Correlated with the decreased drug-Induced abnormalities risk in patients (compare with Allele A)		[ 10]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:            5 Drugs in Total
Mycophenolic acid	Drug Info	Lung Transplantation	Correlated with the decreased drug concentrations in patients (compare with genotypes AG + GG)		[ 11]
Atorvastatin	Drug Info	Hypercholesterolemia	Correlated with the increased drug response in patients (compare with genotypes AG + GG)		[ 12]
Pravastatin	Drug Info	Hypercholesterolemia	Irrelevant to the drug response in patients (compare with genotype GG)		[ 13]
Rocuronium	Drug Info	Muscle Relaxant	Correlated with the decreased drug response in patients (compare with genotypes AG + GG)		[ 14]
Hmg coa reductase inhibitors	N.A.	Coronary Artery Disease	Correlated with the increased creatine kinase in patients (compare with genotype AG)		[ 15]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:            6 Drugs in Total
Rifampicin	Drug Info	Healthy Individuals	Correlated with the decreased drug clearance in healthy individuals (compare with genotypes AA + AG)		[ 1]
Repaglinide	Drug Info	Healthy Individuals	Correlated with the decreased the total area under the plasma concentration-time curve (AUC) of drug and Cmax in healthy individuals (compare with genotype AA)		[ 17]
Irinotecan	Drug Info	Neoplasm	Correlated with the increased neutropenia risk in patients (compare with genotype AA)		[ 18]
Atorvastatin	Drug Info	Hypercholesterolemia	Correlated with the increased reduction in LDL in patients (compare with genotypes AA + AG); Irrelevant to the increased drug response in patients (compare with genotypes AA + AG)		[ 19], [ 20]
Simvastatin	Drug Info	Hypercholesterolemia	Irrelevant to the increased drug response in patients (compare with genotypes AA + AG)		[ 19]
Irinotecan	Drug Info	Non-Small-Cell Lung Carcinoma	Irrelevant to the neutropenia in patients (compare with genotypes AA + AG)		[ 21]
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:            6 Drugs in Total
Mycophenolic acid	Drug Info	Kidney Transplantation	Correlated with the decreased drug clearance in patients (compare with genotype GG)		[ 21]
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased drug clearance in patients (compare with genotype GG)		[ 22]
Irinotecan	Drug Info	Colorectal Neoplasm	Correlated with the increased drug response in patients (compare with genotype GG)		[ 23]
Fluorouracil	Drug Info	Colorectal Neoplasm	Correlated with the increased drug response in patients (compare with genotype GG)		[ 23]
Leucovorin	Drug Info	Colorectal Neoplasm	Correlated with the increased drug response in patients (compare with genotype GG)		[ 23]
Capecitabine	Drug Info	Colorectal Neoplasm	Correlated with the increased drug response in patients (compare with genotype GG)		[ 23]
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:            5 Drugs in Total
Sorafenib	Drug Info	Diarrhea	Correlated with the decreased likelihood of diarrhea in patients (compare with genotype AA)		[ 24]
Atorvastatin	Drug Info	Hypercholesterolemia	Correlated with the increased drug response in patients (compare with genotype AA); Irrelevant to the increased myalgia unspecified risk in patients (compare with genotype AA)		[ 25], [ 26]
Pitavastatin calcium	Drug Info	Healthy Individuals	Correlated with the increased the total area under the plasma concentration-time curve (AUC) of drug and Cmax in healthy individuals (compare with genotype AA)		[ 27]
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Irrelevant to the drug concentrations in patients (compare with genotype AA)		[ 7]
Irinotecan	Drug Info	Neoplasm	Irrelevant to the severity of neutropenia in patients (compare with genotype AA)		[ 29]
Genetic Polymorphism	rs2900478
Site of GPD	chr12:21215863 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A
Minor Allele Frequency	A=0.0895/448 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Hmg coa reductase inhibitors	N.A.	Coronary Artery Disease	Correlated with the decreased drug response in patients (compare with Allele T)		[ 29]
Genetic Polymorphism	rs4149015
Site of GPD	chr12:21130388 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C
Minor Allele Frequency	A=0.0547/274 (Global)
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:            2 Drugs in Total
Pravastatin	Drug Info	Hypercholesterolemia	Correlated with the decreased drug response (compare with genotype GG)		[ 30]
Pravastatin	Drug Info	Healthy Individuals	Correlated with the increased drug AUC0-12 in healthy individuals (compare with genotype GG)		[ 31]
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Irinotecan	Drug Info	Non-Small-Cell Lung Carcinoma	Correlated with the increased neutropenia in patients (compare with genotype GG); Irrelevant to the diarrhea in patients (compare with genotype GG)		[ 20]
Genetic Polymorphism	rs4149032
Site of GPD	chr12:21164857 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.4643/2325 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Rifampicin	Drug Info	Tuberculosis	Correlated with the decreased drug exposure in patients (compare with allele C)		[ 32]
Genetic Polymorphism	rs4149056
Site of GPD	chr12:21178615 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	C=0.0877/439 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:          23 Drugs in Total
Fluvastatin	Drug Info	Muscular Diseases	Correlated with the all statin-induced myopathy and severe myopathy in patients (compare with Allele T)		[ 33]
Simvastatin	Drug Info	Muscular Diseases	Correlated with the all statin-induced myopathy and severe myopathy in patients (compare with Allele T)		[ 33]
Atorvastatin	Drug Info	Muscular Diseases	Correlated with the all statin-induced myopathy and severe myopathy in patients (compare with Allele T); Correlated with the increased drug plasma concentrations in patients (compare with Allele T)		[ 33], [ 34]
Rosuvastatin	Drug Info	Muscular Diseases	Correlated with the all statin-induced myopathy and severe myopathy in patients (compare with Allele T); Correlated with the increased drug plasma concentrations in patients (compare with Allele T)		[ 33], [ 34]
Pravastatin	Drug Info	Muscular Diseases	Correlated with the all statin-induced myopathy and severe myopathy in patients (compare with Allele T); Correlated with the increased the total area under the plasma concentration-time curve (AUC) of drug and Cmax in patients (compare with Allele T)		[ 33], [ 35]
Mycophenolate mofetil	Drug Info	Kidney Transplantation	Correlated with the decreased adverse drug reactions risk in patients (compare with Allele T)		[ 36]
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the decreased drug clearance in patients (compare with Allele T)		[ 3]
Pravastatin	Drug Info	Healthy Individuals	Correlated with the decreased drug metabolism in healthy individuals (compare with Allele T); Correlated with the increased the total area under the plasma concentration-time curve (AUC) of drug in healthy individuals (compare with Allele T)		[ 38], [ 39]
Atorvastatin	Drug Info	Hypercholesterolemia	Correlated with the increased composite adverse events risk in patients (compare with Allele T)		[ 40]
Pravastatin	Drug Info	Hypercholesterolemia	Correlated with the increased composite adverse events risk in patients (compare with Allele T)		[ 40]
Simvastatin	Drug Info	Hypercholesterolemia	Correlated with the increased composite adverse events risk in patients (compare with Allele T)		[ 40]
Rosuvastatin	Drug Info	Hypercholesterolemia	Correlated with the increased drug plasma concentrations in patients (compare with Allele T)		[ 34]
Rosuvastatin	Drug Info	Coronary Artery Disease	Correlated with the increased likelihood of statin-related myopathy in patients (compare with Allele T)		[ 9]
Cytarabine	Drug Info	Acute Myeloid Leukemia	Correlated with the increased likelihood of toxic liver disease in patients (compare with Allele T)		[ 42]
Nateglinide	Drug Info	Diabetes	Irrelevant to the drug pharmacokinetics (compare with Genotype TT)		[ 43]
Atorvastatin	Drug Info	Hyperlipidemias	Irrelevant to the muscular diseases risk in patients (compare with Allele T)		[ 44]
Rosiglitazone	Drug Info	Diabetes Mellitus	Correlated with the increased drug response in patients (compare with Allele T)		[ 45]
Fludarabine	Drug Info	Acute Myeloid Leukemia	Correlated with the increased likelihood of toxic liver disease in patients (compare with Allele T)		[ 42]
Gemtuzumab ozogamicin	Drug Info	Acute Myeloid Leukemia	Correlated with the increased likelihood of toxic liver disease in patients (compare with Allele T)		[ 42]
Idarubicin	Drug Info	Acute Myeloid Leukemia	Correlated with the increased likelihood of toxic liver disease in patients (compare with Allele T)		[ 42]
Hmg coa reductase inhibitors	N.A.	Muscular Diseases	Correlated with the all statin-induced myopathy and severe myopathy in patients (compare with Allele T)		[ 33]
Simvastatin acid	N.A.	Hypercholesterolemia	Correlated with the increased drug concentrations (compare with Genotype TT); Correlated with the increased drug concentrations in patients (compare with Allele T)		[ 46], [ 47]
Hmg coa reductase inhibitors	N.A.	Diabetes Mellitus	Correlated with the increased drug-Induced abnormalities risk in patients (compare with Allele T)		[ 10]
Allele T	Click to Show/Hide the Full List of Affected Drugs:            5 Drugs in Total
Rosuvastatin	Drug Info	Healthy Individuals	Correlated with the increased drug exposure in healthy individuals (compare with allele C)		[ 46]
Mycophenolate mofetil	Drug Info	Kidney Transplantation	Irrelevant to the increased diarrhea risk in patients (compare with allele C); Irrelevant to the increased leukopenia risk in patients (compare with allele C)		[ 47]
Rosuvastatin	Drug Info	Coronary Disease	Irrelevant to the LDL-C response in patients (compare with allele C)		[ 48]
Simvastatin	Drug Info	Coronary Disease	Irrelevant to the LDL-C response in patients (compare with allele C)		[ 48]
Ticagrelor	N.A.	Acute Coronary Syndrome	Correlated with the decreased drug concentrations in patients (compare with allele C)		[ 8]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:          14 Drugs in Total
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the decreased drug response in patients (compare with Genotypes CT + TT)		[ 7]
Rosuvastatin	Drug Info	Hypercholesterolemia	Correlated with the increased drug AUC in patients (p=0.002) and Cmax in patients (p=0.003) (compare with Genotype TT)		[ 50]
Pravastatin	Drug Info	Hypercholesterolemia	Correlated with the increased drug mean peak concentration in plasma and area under the plasma concentration in patients (compare with Genotypes CT + TT); Irrelevant to the drug response in patients (compare with Genotype TT)		[ 13], [ 52]
Lopinavir	Drug Info	HIV Infection	Correlated with the increased drug median plasma Cmin and C2-6 (compare with Genotypes CT + TT)		[ 53]
Simvastatin	Drug Info	Healthy Individuals	Correlated with the increased drug plasma concentrations in healthy individuals (compare with Genotypes CT + TT)		[ 54]
Simvastatin	Drug Info	Myocardial Infarction	Correlated with the increased likelihood of muscular diseases in patients (compare with Genotype TT)		[ 55]
Simvastatin	Drug Info	Muscular Diseases	Correlated with the increased muscular diseases risk in patients (compare with genotype Ct); Irrelevant to the increased drug dose decrease or switch to another cholesterol-lowering drug risk in patients (compare with Genotype TT)		[ 55], [ 56]
Cerivastatin	Drug Info	Muscular Diseases	Correlated with the increased rhabdomyolysis risk in patients (compare with Genotype TT)		[ 57]
Cerivastatin	Drug Info	Rhabdomyolysis	Correlated with the increased rhabdomyolysis risk in patients (compare with Genotype TT)		[ 57]
Repaglinide	Drug Info	Diabetes Mellitus	Correlated with the increased the total area under the plasma concentration-time curve (AUC) of drug (compare with Genotypes CT + TT)		[ 41]
Atorvastatin	Drug Info	Healthy Individuals	Correlated with the increased the total area under the plasma concentration-time curve (AUC) of drug in healthy individuals (compare with Genotype TT)		[ 50]
Fluvastatin	Drug Info	Muscular Diseases	Irrelevant to the increased mean peak concentration in plasma and area under the plasma concentration in patients (compare with Genotypes CT + TT)		[ 52]
Hmg coa reductase inhibitors	N.A.	Muscular Diseases	Correlated with the increased creatine kinase in patients (compare with Genotypes CT + TT); Correlated with the increased drug dose decrease or switch to another cholesterol-lowering drug risk in patients (compare with Genotype TT)		[ 15], [ 56]
Simvastatin acid	N.A.	Healthy Individuals	Correlated with the increased drug concentrations in healthy individuals (compare with Genotype TT)		[ 60]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:          11 Drugs in Total
Simvastatin	Drug Info	Muscular Diseases	Correlated with the decreased drug clearance in patients (compare with Genotype TT); Correlated with the increased muscular diseases risk in patients (compare with Genotype TT)		[ 53], [ 58]
Pravastatin	Drug Info	Coronary Stenosis	Correlated with the decreased drug response in patients (compare with Genotype TT)		[ 59]
Pravastatin	Drug Info	Muscular Diseases	Correlated with the decreased drug response in patients (compare with Genotype TT); Correlated with the increased drug AUC0-12 in patients (compare with Genotype TT); Correlated with the increased drug metabolism in patients (compare with Genotype TT)		[ 31], [ 59], [ 60]
Pravastatin	Drug Info	Transplantation	Correlated with the drug response in patients (compare with Genotype TT)		[ 60]
Pravastatin	Drug Info	Healthy Individuals	Correlated with the increased drug AUC and Cmax in healthy individuals (compare with Genotype TT); Correlated with the increased drug AUC0-12 in healthy individuals (compare with Genotype TT)		[ 31], [ 62]
Repaglinide	Drug Info	Healthy Individuals	Correlated with the increased drug concentrations in healthy individuals (compare with Genotype TT)		[ 63]
Atorvastatin	Drug Info	Healthy Individuals	Correlated with the increased drug exposure in healthy individuals (compare with Genotype TT)		[ 64]
Rosuvastatin	Drug Info	Healthy Individuals	Correlated with the increased drug exposure in healthy individuals (compare with Genotype TT)		[ 64]
Pravastatin	Drug Info	Hyperlipoproteinemia	Irrelevant to the increased drug metabolism in patients (compare with Genotype TT)		[ 60]
Irinotecan	Drug Info	Neoplasm	Irrelevant to the severity of neutropenia in patients (compare with Genotype TT)		[ 28]
Simvastatin acid	N.A.	Hypercholesterolemia	Correlated with the increased drug exposure in patients (compare with Genotype TT)		[ 66]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:          12 Drugs in Total
Atorvastatin	Drug Info	Coronary Artery Disease	Correlated with the a nearly tripled increased percentage of drug AUC (0 - 48) values in patients (compare with genotype CC)		[ 64]
Rifampicin	Drug Info	Tuberculosis	Correlated with the a nearly tripled increased percentage of drug AUC (0 - 48) values in patients (compare with genotype CC)		[ 64]
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the decreased drug concentrations in patients (compare with genotypes CC + CT)		[ 65]
Rosuvastatin	Drug Info	Hypercholesterolemia	Correlated with the decreased drug plasma concentrations in patients (compare with genotypes CC + CT); Irrelevant to the percentage change in LDL-cholesterol levels in patients (compare with Genotypes CT + TT)		[ 66]
Mycophenolate mofetil	Drug Info	Kidney Transplantation	Correlated with the increased adverse drug reaction risk in patients (compare with genotype CC)		[ 36]
Fluorouracil	Drug Info	Breast Neoplasm	Correlated with the increased alcoholism risk in patients (compare with genotype GG)		[ 68]
Epirubicin	Drug Info	Breast Neoplasm	Correlated with the increased alcoholism risk in patients (compare with genotype GG)		[ 68]
Docetaxel	Drug Info	Breast Neoplasm	Correlated with the increased alcoholism risk in patients (compare with genotype GG)		[ 68]
Doxorubicin	Drug Info	Breast Neoplasm	Correlated with the increased alcoholism risk in patients (compare with genotype GG)		[ 68]
Cyclophosphamide	Drug Info	Breast Neoplasm	Correlated with the increased alcoholism risk in patients (compare with genotype GG)		[ 68]
Fluvastatin	Drug Info	Muscular Diseases	Correlated with the increased drug response as in patients (compare with genotypes CC + CT)		[ 13]
Goserelin	Drug Info	Breast Neoplasm	Correlated with the increased alcoholism risk in patients (compare with genotype GG)		[ 68]
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:          12 Drugs in Total
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the decreased drug clearance in patients (compare with Genotype TT); Correlated with the decreased drug dose in patients (compare with Genotype TT)		[ 22], [ 68]
Mercaptopurine	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the decreased drug dose in patients (compare with Genotype TT)		[ 68]
Atorvastatin	Drug Info	Obesity	Correlated with the decreased drug oral clearance in patients (compare with Genotype TT)		[ 70]
Atorvastatin	Drug Info	Muscular Diseases	Correlated with the increased drug dose decrease or switch to another cholesterol-lowering drug risk in patients (compare with Genotype TT); Correlated with the increased likelihood of drug toxicity, muscular diseases, rhabdomyolysis and toxic liver disease in patients (compare with Genotype TT); Irrelevant to the increased drug dose decrease or switch to another cholesterol-lowering drug risk in patients (compare with Genotype TT)		[ 54], [ 72]
Sn-38	Drug Info	Non-Small-Cell Lung Carcinoma	Correlated with the increased drug dose in patients (compare with Genotype TT)		[ 20]
Enalapril	Drug Info	Essential Hypertension	Correlated with the increased likelihood of cough in patients (compare with Genotype TT)		[ 74]
Simvastatin	Drug Info	Hyperlipidemias	Correlated with the increased muscular diseases risk in patients (compare with Genotype TT)		[ 42]
Irinotecan	Drug Info	Non-Small-Cell Lung Carcinoma	Correlated with the increased neutropenia risk in patients (compare with Genotype TT)		[ 20]
Irinotecan	Drug Info	Neoplasm	Irrelevant to the diarrhea in patients (compare with Genotype TT)		[ 20]
Atorvastatin	Drug Info	Hypercholesterolemia	Irrelevant to the increased myalgia unspecified risk in patients (compare with Genotype TT)		[ 25]
Rosuvastatin	Drug Info	Muscular Diseases	Irrelevant to the increased myalgia unspecified risk in patients (compare with Genotype TT)		[ 77]
Simvastatin acid	N.A.	Hypercholesterolemia	Correlated with the increased drug concentrations (compare with Genotype TT)		[ 78]
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:            3 Drugs in Total
Sorafenib	Drug Info	Thrombocytopenia	Correlated with the increased likelihood of disease in patients (compare with genotype CC)		[ 24]
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Irrelevant to the drug concentrations in patients (compare with genotype CC)		[ 7]
Pravastatin	Drug Info	Hypercholesterolemia	Irrelevant to the the drug response in patients (compare with genotype CC)		[ 76]
Genetic Polymorphism	rs4149081
Site of GPD	chr12:21225087 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	A=0.2188/1096 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the drug clearance in patients (compare with allele A); Correlated with the increased gastrointestinal toxicity risk in patients (compare with Allele A)		[ 5]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:            2 Drugs in Total
Rosuvastatin	Drug Info	Coronary Disease	Correlated with the increased LDL-C reduction in patients (compare with genotypes AG + GG)		[ 48]
Simvastatin	Drug Info	Coronary Disease	Correlated with the increased LDL-C reduction in patients (compare with genotypes AG + GG)		[ 48]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:            2 Drugs in Total
Rosuvastatin	Drug Info	Coronary Disease	Correlated with the increased LDL-C reduction in patients (compare with genotype GG)		[ 48]
Simvastatin	Drug Info	Coronary Disease	Correlated with the increased LDL-C reduction in patients (compare with genotype GG)		[ 48]
Genetic Polymorphism	rs4363657
Site of GPD	chr12:21215788 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	C=0.2149/1076 (Global)
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Simvastatin	Drug Info	Myocardial Infarction	Correlated with the increased likelihood of muscular diseases in patients (compare with Genotype TT)		[ 53]
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Rosuvastatin	Drug Info	Muscular Diseases	Irrelevant to the increased myalgia unspecified risk in patients (compare with Genotype TT)		[ 72]
Genetic Polymorphism	rs10841753
Site of GPD	chr12:21168436 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	C=0.2352/1178 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Irrelevant to the drug response in patients (compare with Allele T)		[ 7]
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the decreased drug concentrations in patients (compare with genotype CC); Irrelevant to the mucositis risk in patients (compare with genotype CC)		[ 7]
Genetic Polymorphism	rs2291073
Site of GPD	chr12:21172880 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>G
Minor Allele Frequency	G=0.2925/1465 (Global)
Genotypes GT + TT	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Lovastatin	Drug Info	Hypercholesterolemia	Correlated with the increased drug response (compare with genotype GG)		[ 13]
Genetic Polymorphism	rs2291075
Site of GPD	chr12:21178691 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.4155/2081 (Global)
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:            4 Drugs in Total
Etoposide	Drug Info	Acute Myeloid Leukemia	Correlated with the increased event-free survival and overall survival in patients (compare with genotype CC)		[ 75]
Mitoxantrone	Drug Info	Acute Myeloid Leukemia	Correlated with the increased event-free survival and overall survival in patients (compare with genotype CC)		[ 75]
Daunorubicin	Drug Info	Acute Myeloid Leukemia	Correlated with the increased event-free survival and overall survival in patients (compare with genotype CC)		[ 75]
Cytarabine	Drug Info	Acute Myeloid Leukemia	Correlated with the increased event-free survival and overall survival in patients (compare with genotype CC)		[ 75]
Genetic Polymorphism	rs4149036
Site of GPD	chr12:21174806 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A
Minor Allele Frequency	A=0.3542/1774 (Global)
Genotypes AC + CC	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Atorvastatin	Drug Info	Coronary Artery Disease	Correlated with the increased drug response in patients (compare with genotype AA)		[ 13]
References
1	Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance. Pharmacotherapy. 2014 Mar;34(3):265-71.
2	Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics. 2008 Sep;9(9):1217-27.
3	Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood. 2013 Feb 7;121(6):898-904.
4	PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Hum Mol Genet. 2012 Nov 1;21(21):4793-804.
5	Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol. 2009 Dec 10;27(35):5972-8.
6	Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma. Pharmacogenet Genomics. 2014 Oct;24(10):514-21.
7	Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia. Oncotarget. 2017 Jun 6;8(23):37761-37772.
8	Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. Eur Heart J. 2015 Aug 1;36(29):1901-12.
9	SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. Eur J Clin Pharmacol. 2017 Nov;73(11):1409-1416.
10	Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin Pharmacol Ther. 2011 Feb;89(2):210-6.
11	Impact of Single Nucleotide Polymorphisms (SNPs) on Immunosuppressive Therapy in Lung Transplantation. Int J Mol Sci. 2015 Aug 25;16(9):20168-82.
12	Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population. J Clin Pharm Ther. 2016 Jun;41(3):329-33.
13	An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J. 2005;5(6):352-8.
14	Role of SLCO1B1, ABCB1, and CHRNA1 gene polymorphisms on the efficacy of rocuronium in Chinese patients. J Clin Pharmacol. 2015 Mar;55(3):261-8.
15	Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2. Eur J Clin Pharmacol. 2014 May;70(5):539-47.
16	Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. Pharmacogenet Genomics. 2008 Nov;18(11):937-42.
17	Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study. Pharmacogenomics J. 2016 Feb;16(1):54-9.
18	Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals. Eur J Clin Pharmacol. 2013 Jun;69(6):1269-74.
19	Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response. Int J Mol Sci. 2011;12(9):5815-27.
20	Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer. 2009 Jan;63(1):115-20.
21	Population pharmacogenetic pharmacokinetic modeling for flip-flop phenomenon of enteric-coated mycophenolate sodium in kidney transplant recipients. Eur J Clin Pharmacol. 2014 Oct;70(10):1211-9.
22	Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood. 2013 Jun 27;121(26):5145-53.
23	SLCO1B1 and SLC19A1 gene variants and irinotecan-induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer. PLoS One. 2013 Oct 15;8(10):e77223.
24	Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity. Pharmacogenomics. 2016 Sep;17(14):1483-90.
25	SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol. 2012 Mar;68(3):273-9.
26	SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals. Int J Mol Sci. 2015 Aug 31;16(9):20609-19.
27	OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers. J Clin Pharm Ther. 2010 Feb;35(1):99-104.
28	UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol. 2009 Apr;14(2):136-42.
29	Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun. 2014 Oct 28;5:5068.
30	Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenet Genomics. 2005 May;15(5):303-9.
31	High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics. 2004 Jul;14(7):429-40.
32	The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrob Agents Chemother. 2011 Sep;55(9):4122-7.
33	SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin Pharmacol Ther. 2013 Dec;94(6):695-701.
34	Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet. 2013 Aug;6(4):400-8.
35	Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin Pharmacol Ther. 2006 May;79(5):419-26.
36	SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenomics. 2010 Dec;11(12):1703-13.
37	Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther. 2003 Jun;73(6):554-65.
38	Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther. 2004 May;75(5):415-21.
39	The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009 Oct 20;54(17):1609-16.
40	Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin. Pharmacogenomics J. 2013 Aug;13(4):335-41.
41	Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. J Clin Pharmacol. 2008 Mar;48(3):311-21.
42	Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J. 2012 Jun;12(3):233-7.
43	CYP2C8 and SLCO1B1 Variants and Therapeutic Response to Thiazolidinediones in Patients With Type 2 Diabetes. Diabetes Care. 2016 Nov;39(11):1902-1908.
44	Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid. Pharmacogenet Genomics. 2015 Dec;25(12):595-608.
45	Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations. J Cardiovasc Pharmacol. 2015 Jul;66(1):80-5.
46	Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. Eur J Clin Pharmacol. 2015 Mar;71(3):329-40.
47	Mycophenolic acid-related diarrhea is not associated with polymorphisms in SLCO1B nor with ABCB1 in renal transplant recipients. Pharmacogenet Genomics. 2012 Jun;22(6):399-407.
48	Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia. Pharmacogenet Genomics. 2012 Nov;22(11):803-6.
49	Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2007 Dec;82(6):726-33.
50	SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther. 2006 Oct;80(4):356-66.
51	HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics. 2010 Feb;20(2):112-20.
52	SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 2006 Dec;16(12):873-9.
53	SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med. 2008 Aug 21;359(8):789-99.
54	The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenet Genomics. 2014 Jan;24(1):43-51.
55	Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.
56	Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach. Pharm Res. 2015 Jun;32(6):1864-83.
57	Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach. Clin Pharmacol Ther. 2014 Jul;96(1):90-100.
58	SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. Br J Clin Pharmacol. 2007 Sep;64(3):346-52.
59	Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. Br J Clin Pharmacol. 2006 Jun;61(6):706-15.
60	Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics. 2007 Aug;17(8):647-56.
61	Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population. Eur J Clin Pharmacol. 2018 Aug;74(8):1021-1028.
62	Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect? Eur J Clin Pharmacol. 2015 Mar;71(3):341-55.
63	The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition. Pharmacogenomics. 2017 Apr;18(5):459-469.
64	Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
65	Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia. Br J Haematol. 2014 Aug;166(3):410-20.
66	Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Pharmacogenomics. 2013 Aug;14(11):1283-94.
67	SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study. BMC Cancer. 2016 May 27;16:337.
68	SLCO1B1 Polymorphisms are Associated With Drug Intolerance in Childhood Leukemia Maintenance Therapy. J Pediatr Hematol Oncol. 2018 Jul;40(5):e289-e294.
69	Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects. Clin Pharmacol Ther. 2013 Mar;93(3):275-82.
70	ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a case-control study. Pharmacogenomics. 2015 Jul;16(8):803-15.
71	SLCO1B1 Variants and Angiotensin Converting Enzyme Inhibitor (Enalapril)-Induced Cough: a Pharmacogenetic Study. Sci Rep. 2015 Nov 26;5:17253.
72	Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. Am Heart J. 2013 Jun;165(6):1008-14.
73	Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics. J Clin Pharmacol. 2018 Jun;58(6):823-833.
74	The effects of a single nucleotide polymorphism in SLCO1B1 on the pharmacodynamics of pravastatin. Br J Clin Pharmacol. 2012 Feb;73(2):303-6.
75	Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. Clin Pharmacol Ther. 2016 Jun;99(6):651-60.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.